Lexaria Bioscience Corp

Lexaria Bioscience doubles down on oral GLP‑1 delivery, unveiling a transparent investor video series and extending a key MTA, while its stock lingers at $0.66

Lexaria Bioscience Corp boosts API bioavailability with innovative drug delivery tech, aiming to transform medication absorption—find out how it could reshape pharma.

Lexaria Bioscience’s 2025 breakthrough in oral GLP‑1 delivery with DehydraTECH™ positions the company to capture a booming market, unlocking new therapeutic avenues for investors.

Lexaria Bioscience reports new Phase 1b data on its DehydraTECH‑semaglutide platform, and announces a 2.75 million‑share secondary sale by existing shareholders to boost liquidity and extend its 2026 runway.

Lexaria Bioscience: Can its breakthrough API‑absorption tech beat a shaky stock? Dive into the company’s innovation, IP, and financial hurdles.

Lexaria Bioscience Corp has reached a key milestone in its Phase 1b GLP-1 study, completing all patient dosing and clinical testing, with final results expected by the end of 2025.

Lexaria Bioscience Corp. believes its DehydraTECH technology can significantly reduce side effects in the GLP-1 industry, a market projected to reach $156 billion by 2030.

Lexaria Bioscience Corp is pioneering pharmaceutical efficiency with its innovative technology that enhances the bioavailability of active pharmaceutical ingredients, positioning the company as a leader in the field of healthier ingestion methods.

Lexaria Bioscience Corp is a Canadian healthcare company pioneering innovative pharmaceutical delivery systems, enhancing the efficiency of active ingredients and reimagining the patient experience.

Lexaria Bioscience Corp’s innovative technology has sparked excitement in the pharmaceutical industry, but its recent financial decisions, including a $2 million direct offering, have raised concerns and led to a decline in investor confidence.